with the M1 isoform [3] . Rescue of cells subjected to shRNA knock-down of PKM2 with PKM1 also showed reduced tumor formation in a xenograft model. Pyruvate kinase functions in glycolysis to catalyze conversion of phosphoenolpyruvate (PEP) to pyruvate with concomitant generation of ATP from ADP. There are four mammalian PK isoforms encoded by two genes located on two distinct chromosomes [9] [10] [11] [12] [13] . Encoded by PKLR, PKR is found in erythrocytes and PKL is expressed in both the liver and kidney. The PKM gene also has two splice varients; PKM1 that is predominantly found in muscle and brain tissue and PKM2 that is expressed in some adult tissues, embryonic tissues and tumor cells [1] . Regardless of the isoform, the active form of PK is a tetramer. PKM2, PKL and PKR are allosterically activated in a feed forward mechanism by fructose-1,6-bisphosphate (FBP) while PKM1, which is expressed in tissues with high ATP requirements, does not require allosteric activation [14] . While it has been reported that PKM2 in tumors exists predominantly as an inactive dimer [1, 15] , exactly how this contributes to tumorigenesis and the Warburg effect is still unknown.
It has been hypothesized that cancer cells benefit from the low activity of PKM2 to increase levels of glycolytic intermediates for use in anabolic processes including nucleic acid, amino acid, and lipid syntheses [15] . This suggests that pharmacological activation of PKM2 to levels associated with PKM1 may inhibit cell proliferation as well as be a potential therapeutic strategy for cancer. Our group has previously reported two chemotypes capable of activating PKM2 including a series of diarylsulfonamides [16] and a series of thieno [3,2-b] pyrrole [3,2-d] pyridazinones [17] (exemplified by 1 and 2 respectively in Figure 1 ). Here, we describe the development of a series of PKM2 activators derived from the 2-oxo-N-aryltetrahydroquinoline-6-sulfonamide lead, 3.
Using our previously described qHTS assay for PKM2 activators [16] , compound 3 was found to have an AC 50 = 790 nM in the primary screen. Resynthesis of the hit as well as the majority of analogs described in Tables 1 and 2 was accomplished via base-mediated coupling of commercially available anilines and sulfonyl chlorides in DMF, as represented in Scheme 1. An array of commercially available anilines were coupled with sulfonyl chlorides using either Hunig's base or pyridine in DMF solvent.
We began by looking at potential modification of the aryl linkage, but the importance of the NH-sulfonamide was apparent after both the N-methylsulfonamide and amide-linked derivatives showed a complete loss in activity (data not shown). We next investigated the importance of the 3,4-dihydroquinolin-2(1H)-one moiety by removing of the amide functionality to generate a number of simple substituted benzene derivates (5 -9). While a number of these retained activity, they all showed significantly diminished potency (≥ 20-fold) and/or efficacy. Informed by these results, we next investigated various amide, urea and carbamate derivatives as well as heteroatom inclusion. A few interesting SAR points from these modifications were: placing the amide carbonyl outside of the ring (14 and 22) , changing the amide ring structure to a 5-or 7-membered rings (15 and 16) or removing the cyclic nature of the amide (13 and 17), all resulted in a significant loss of potency. In general, most analogs that altered the 6-membered lactam moiety saw a considerable drop in activity.
The next SAR we wanted to explore was altering the 3,4-dimethylaniline moiety by addition of a variety of substituted anilines to the commercially available 2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonyl chloride (Table 2) . Preference for substitution of hydrophobic groups at the meta-position quickly emerged as a key for potency as the 3-methyl (24), 3-fluoro (27) and 3-chloro (29) analogs all had AC 50 values <800 nM. Notably, the 3-methoxy analog (34) saw a potency drop of >4-fold compared to the 3-methyl version. All ortho-substituents tested resulted in a marked decrease in activity while more tolerance was observed at the para-position. Noteworthy inactive analogs were pyridine derivatives 31 and 32 as well as the quinoline derivative (39) for which the non-nitrogenous 2-naphthalene analog (38) had reasonable activity (1.3 μM). Tethering the hydrophobic dimethyl group in a dihydroindene ring resulted in a much less potent analog (40), while combinations of methyl, fluoro and chloro at the 3-and 4-positions resulted in a number of analogs with good potencies (41 -46). Both the 3-chloro-4-methyl (41) and 3-chloro-4-fluoro (45) derivatives had potencies <300 nM, so these, along with the original 3,4-dimethyl substitution patterns were chosen as motifs to carry on.
Derivatives with various substituents at the 6-position of 3,4-dihydroquinolin-2(1H)-one-7-sulfonamides, the 7-position of 3,4-dihydroquinolin-2(1H)-one-6-sulfonamides, and the 6-position of 3-oxo-3,4-dihydro-2H-benzo[b] [1, 4] oxazine-7-sulfonamides were examined next ( Table 3 ). 6-bromo-3-oxo-3,4-dihydro-2H-benzo[b] [1, 4] oxazine-7-sulfonyl chloride was coupled with 3,4-dimethylaniline and then subjected to standard Suzuki cross coupling conditions to provide a variety of aryl substituted dihydro-2H-benzo[b] [1, 4] oxazines (Scheme 2A). Generally, the addition of aryl and heteroaryl substituents resulted in decreased reactivity (exemplified by 47 and 48 in Table 3 ).
Good activity was obtained starting with 7-fluoro-2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonyl chloride to generate 51 with a potency of 210 nM. This particular analog was further modified by introduction of nitrogen nucleophiles through S N Ar reactions in acetonitrile (Scheme 2B). Significant SAR was seen with substitution of a variety of these analogs. Sterically larger groups like N,N-dimethylpyrrolidin-3-amine (56) and piperidine (57) resulted loss of activity while smaller dimethyl-(52) and methyl-amine (54) derivatives retained activity. With the realization that small amines were tolerated at this position a few analogs were generated in an effort to improve both solubility and potency (58 -63). The racemic alaninol derivative provided high aqueous kinetic solubility (>120 μM in PBS buffer) while retaining low nanomolar potency (61). Preparation of the enantiopure versions with (S)-and (R)-alaninol resulted the (S)-derivative being 4-fold more potent than its enantiomer (880 nM for 62 vs 170 nM for 63). Combination of 7-fluoro or 7-(S)-alaninol derivatives with the best aniline analogs from Table 2 gave compounds 64 -70, which all have low nanomolar activity with good maximum response. Interestingly, it was discovered that flipping the amide orientation to generate the 6-chloro-and 6-(dimethylamino)-3,4-dihydroquinolin-2(1H)-one-7-sulfonamide derivatives gave potent analogs 71 -73. These results led us to develop chemistry to quickly access these constitutional isomers (Scheme 3). The sulfonylation of 78 generated regioisomers that after coupling with 79 afforded 74a and 74b or with aniline 80 afforded 75a and 75b. Analogs 74a and 75a had weak activity (>5μM) while their regioisomers, 74b and 75b had no activity (data not shown). The incorporation of the (S)-alaninol through Ullmann chemistry for the active bromide isomers generated 76a and 77a, but rather surprisingly, these compounds had significantly diminished activity compared to analogs 63 and 68 respectively. Buchwald chemistry was required for the conversion of 74b and 75b to the alaninol-substituted derivatives 76b and 77b, respectively. Both of these analogs proved to be inactive, as well (data not shown).
Having generated a number of analogs with potencies <200 nM, a select few were taken on to assess their selectivity against the other PK isoforms ( Figure 2 ). All analogs tested had no activity against the R or M1 isoforms and showed only minimal activation of the L isoform (≤25% at 57.5 μM). Compound 66 was also tested for its ability to modulate PEP and ADP affinity for hPKM2 ( Figure 3) . As with our previously reported activators [16, 17] , this analog showed significant decrease in K m for PEP (K m ~ 1.9 mM without 66, 0.4 mM with 66) while not affecting the K m of ADP (K m ~ 0.1 mM in both conditions). A number of analogs were also taken on to test their cell permeability and in vitro microsomal stability in both mouse and human liver microsomes (Caco-2, MLM and HLM in Table 4 ). While the original lead (3) had moderate Caco-2 permeability with an efflux ratio <1, it had poor microsomal stability in both mouse and human liver microsomes (t 1/2 <20 minutes). It became apparent that while the alaninol substituent provided good solubility and potency, high efflux ratios and reduced MLM half lives were attributable to the incorporation of this side-chain (68 and 69 in Table 4 ). A more drastic reduction in microsomal stability was seen with the N-methyl-and N,N-dimethyl-derivatives 52 and 54 both having half lives <25 minutes. This data suggests that alkyl-amine substitution at this position engenders the molecules with efflux and/or microsomal stability liabilities. Compounds showing good permeability and efflux ratios (≤1) had either hydrogen or fluorine substituents at the 7-position (3, 64 and 66) . The metabolic liabilities of the meta-and para-groups was assessed by comparing analogs 51, 64 and 66. Switching the meta-methyl group to a meta-chlorine slightly decreased both human and mouse microsomal stability (compare 64 to 51). Further, switching the para-methyl group on 64 to a para-fluorine on 66 saw a marked increase in both HLM and MLM with a half life of 277.2 and 117.5 minutes respectively.
In conclusion, we have developed a third novel chemotype capable of activating PKM2. These molecules, based on the 2-oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide scaffold, have low nanomolar potency with a notable analog, 66, having an AC 50 of 90 nM with selectivity over other PK isoforms, good Caco-2 permeability, a low efflux ratio (0.84) and high microsomal stability (t 1/2 = 277.2 min in HLM and 117.5 min in MLM). Pyruvate Kinase Isoform Selectivity Profile. General Synthetic Methodology Used to Access Analogs in Tables 1 and 2 .
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